Announcements Trials

Browse Landscape

Phase

Phase 1 2 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 13 Triple Negative Breast Neoplasms 7 Prostatic Neoplasms 7 Neoplasms 6 Ovarian Neoplasms 4 Neoplasm Metastasis 4 Endometrial Neoplasms 2 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Premenopausal HR+/HER2- Metastatic Breast Cancer 1 Pheochromocytoma 1 Pathologic Complete Response 1 Paraganglioma 1 Pancreatic Neoplasms 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Lymphoma, Non-Hodgkin 1 Lung Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Hemangiosarcoma 1 Glioma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Extensive Stage Lung Small Cell Carcinoma 1 Colorectal Neoplasms 1 Carcinoma, Transitional Cell 1

Interventions

Bevacizumab 234 Fluorouracil 220 Oxaliplatin 216 Irinotecan 215 Leucovorin 199 Capecitabine 153 Cetuximab 146 Panitumumab 70 Folfox protocol 51 regorafenib 43 Radiotherapy 38 pembrolizumab 37 IFL protocol 36 HMPL-013 36 trifluridine tipiracil drug combination 32 Nivolumab 32 Drug Therapy 26 Neoadjuvant Therapy 24 Trifluridine 18 Celecoxib 18 tislelizumab 17 XELOX 17 sintilimab 16 Trastuzumab 16 durvalumab 15 atezolizumab 15 aflibercept 15 Chemotherapy, Adjuvant 15 Biopsy 15 apatinib 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Colorectal Neoplasms × talazoparib × Clear all

NCT05725200 2023-02-21

EVIDENT

Oslo University Hospital

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡